Expert Interview
A Second View: A look at the potential of LY3462817 (Peresolimab) - a PD-1 Antibody Agonist in Rheumatoid Arthritis
Ticker(s): LLYInstitution: Rheumatology Therapeutics Medical Center
- Board-certified in both rheumatology and internal medicine.
- Areas of interest include Rheumatoid Arthritis, Osteoarthritis, Spondyloarthropathies, Lupus, Scleroderma, Mixed Connective Tissue Disease, Sarcoidosis, Osteoporosis, Gout, Inflammatory Myopathies, Vasculitis
- Currently manages 500 patients with rheumatoid Arthritis
- Familiar with the mechanism of action for Peresolimab
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
